Sensei Biotherapeutics (SNSE) Competitors $8.61 +0.23 (+2.74%) Closing price 06/27/2025 03:56 PM EasternExtended Trading$8.63 +0.02 (+0.23%) As of 06/27/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SNSE vs. ARTV, CLNN, KPTI, ATHE, ACRV, VOR, EGRX, AKTX, ELYM, and ESLAShould you be buying Sensei Biotherapeutics stock or one of its competitors? The main competitors of Sensei Biotherapeutics include Artiva Biotherapeutics (ARTV), Clene (CLNN), Karyopharm Therapeutics (KPTI), Alterity Therapeutics (ATHE), Acrivon Therapeutics (ACRV), Vor Biopharma (VOR), Eagle Pharmaceuticals (EGRX), Akari Therapeutics (AKTX), Eliem Therapeutics (ELYM), and Estrella Immunopharma (ESLA). These companies are all part of the "pharmaceutical products" industry. Sensei Biotherapeutics vs. Its Competitors Artiva Biotherapeutics Clene Karyopharm Therapeutics Alterity Therapeutics Acrivon Therapeutics Vor Biopharma Eagle Pharmaceuticals Akari Therapeutics Eliem Therapeutics Estrella Immunopharma Artiva Biotherapeutics (NASDAQ:ARTV) and Sensei Biotherapeutics (NASDAQ:SNSE) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, risk, earnings, dividends and media sentiment. Does the media prefer ARTV or SNSE? In the previous week, Artiva Biotherapeutics had 3 more articles in the media than Sensei Biotherapeutics. MarketBeat recorded 4 mentions for Artiva Biotherapeutics and 1 mentions for Sensei Biotherapeutics. Sensei Biotherapeutics' average media sentiment score of 1.89 beat Artiva Biotherapeutics' score of 0.63 indicating that Sensei Biotherapeutics is being referred to more favorably in the news media. Company Overall Sentiment Artiva Biotherapeutics Positive Sensei Biotherapeutics Very Positive Do institutionals & insiders have more ownership in ARTV or SNSE? 10.5% of Sensei Biotherapeutics shares are owned by institutional investors. 21.4% of Artiva Biotherapeutics shares are owned by insiders. Comparatively, 23.2% of Sensei Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Do analysts rate ARTV or SNSE? Artiva Biotherapeutics currently has a consensus target price of $17.80, indicating a potential upside of 1,110.88%. Sensei Biotherapeutics has a consensus target price of $90.00, indicating a potential upside of 945.30%. Given Artiva Biotherapeutics' higher possible upside, analysts plainly believe Artiva Biotherapeutics is more favorable than Sensei Biotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Artiva Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Sensei Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 Which has higher earnings & valuation, ARTV or SNSE? Sensei Biotherapeutics has lower revenue, but higher earnings than Artiva Biotherapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArtiva Biotherapeutics$250K143.24-$65.37MN/AN/ASensei BiotherapeuticsN/AN/A-$30.16M-$23.00-0.37 Is ARTV or SNSE more profitable? Sensei Biotherapeutics' return on equity of -66.72% beat Artiva Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Artiva BiotherapeuticsN/A -75.95% -39.51% Sensei Biotherapeutics N/A -66.72%-57.10% SummarySensei Biotherapeutics beats Artiva Biotherapeutics on 7 of the 12 factors compared between the two stocks. Get Sensei Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SNSE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SNSE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNSE vs. The Competition Export to ExcelMetricSensei BiotherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.56M$2.84B$5.48B$8.87BDividend YieldN/A2.70%5.35%4.15%P/E Ratio-0.3721.1626.2119.66Price / SalesN/A282.55386.95105.10Price / CashN/A43.1436.4056.81Price / Book0.287.207.905.44Net Income-$30.16M-$55.15M$3.16B$249.37M7 Day Performance12.40%0.76%3.08%3.98%1 Month Performance45.93%6.31%6.02%5.29%1 Year Performance-30.58%-0.21%32.07%17.08% Sensei Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNSESensei Biotherapeutics4.8182 of 5 stars$8.61+2.7%$90.00+945.3%-35.3%$10.56MN/A-0.3740Positive NewsGap DownARTVArtiva Biotherapeutics2.6336 of 5 stars$1.62+2.5%$17.80+998.8%N/A$38.49M$250K0.0081News CoverageHigh Trading VolumeCLNNClene3.0004 of 5 stars$4.10-4.2%$40.00+875.6%-49.1%$38.45M$340K-1.01100Positive NewsKPTIKaryopharm Therapeutics4.1631 of 5 stars$4.33-1.1%$43.20+897.7%-69.9%$37.84M$145.24M-0.33380Positive NewsGap DownATHEAlterity Therapeutics2.653 of 5 stars$4.37+4.0%$12.00+174.6%+120.8%$37.24MN/A0.0010Gap UpACRVAcrivon Therapeutics2.8478 of 5 stars$1.18flat$17.71+1,401.2%-79.2%$37MN/A-0.5358VORVor Biopharma3.9145 of 5 stars$0.29+20.7%$7.06+2,333.5%-7.0%$36.24MN/A-0.18140Trending NewsAnalyst ForecastOptions VolumeGap UpHigh Trading VolumeEGRXEagle Pharmaceuticals2.2008 of 5 stars$2.79-3.0%N/A-42.2%$36.23M$257.55M0.00100News CoverageGap DownAKTXAkari Therapeutics1.623 of 5 stars$1.16+3.6%N/A-56.8%$36.04MN/A0.009News CoveragePositive NewsELYMEliem TherapeuticsN/A$1.21-1.6%N/A-82.7%$36MN/A-2.289ESLAEstrella Immunopharma2.5957 of 5 stars$0.92-7.1%$16.00+1,639.1%-5.3%$35.80MN/A-3.54N/APositive NewsGap Down Related Companies and Tools Related Companies ARTV Alternatives CLNN Alternatives KPTI Alternatives ATHE Alternatives ACRV Alternatives VOR Alternatives EGRX Alternatives AKTX Alternatives ELYM Alternatives ESLA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SNSE) was last updated on 6/28/2025 by MarketBeat.com Staff From Our Partners3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sensei Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sensei Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SNSE Stock Free SNSE Stock Alerts